Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

Perhaps this will shed a little more light

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
CallMeCrazy Member Profile
 
Followed By 22
Posts 1,057
Boards Moderated 0
Alias Born 11/12/13
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 9:24:21 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/22/2019 6:01:03 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/17/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/30/2019 4:38:42 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/20/2019 4:36:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:34:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:52:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:51:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/13/2019 4:11:11 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/2/2019 4:29:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/22/2019 9:30:41 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 10:16:34 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:19:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 7:33:24 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/10/2019 7:32:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/8/2019 4:05:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/31/2019 4:18:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2019 4:17:16 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/22/2019 12:08:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2019 4:32:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/18/2018 5:02:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2018 7:07:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2018 7:02:14 AM
CallMeCrazy   Sunday, 10/20/19 11:20:07 AM
Re: Williamsc post# 274916
Post # of 276505 
Perhaps this will shed a little more light

Quote:
KEVETRIN DAMPENS MYC EXPRESSION AND CELLULAR METABOLISM IN ACUTE MYELOID LEUKEMIA

Results:
The TP53-wt cell line showed a sensibility only at the highest drug concentration with a decreased cell viability and a significant increase in Annexin V+ cells (54.95 ± 5.63 % vs 12.53 ± 6.15 % of the CTRL). KASUMI-1 cell line showed a significant dose- and time-dependent cell growth inhibition and apoptosis increase with 79.70 ± 4.57 % of Annexin V+ cells at 60 µg/ml (vs 13.18 ± 0.80 % of the CTRL). Short-term (6 h) kevetrin treatment induced few alterations of the overall transcriptional program, with a differential expression of FOXK2 and STAT5A, which were 2-fold downregulated in KASUMI-1. Moreover, metallothionein 1 and 2 were upregulated by kevetrin exposure in both cell lines. After prolonged kevetrin treatment (48 h) we found 1024 upregulated and 1563 downregulated genes in MOLM-13 cell line, whereas KASUMI-1 showed increased expression of 325 and decreased levels of 1535 genes. Kevetrin exposure targeted also a common core transcriptional program in the selected models, including 162 upregulated and 812 downregulated genes. Enrichment analysis of the core transcripts showed that upregulated genes were mainly involved in transcription, nucleosome assembly and telomere organization, apoptosis, autophagy, NF-kB pathway and MAPK activity. Downregulated genes were mostly involved in cell cycle, DNA repair, biosynthetic processes, bioenergetics, translation, telomere maintenance and splicing. Among the most relevant genes we found critical regulators of myelopoiesis and leukemogenesis, such as MYC, MYB, BCL11A and EZH1, leukemia-related genes involved in unfolded protein response (JUN), signaling, glycolysis (HK2), DNA methylation (IDH2) and the tumor suppressor gene TP53. GSEA of microarray data showed that kevetrin-treated cells shared the downregulation of glycolysis, DNA repair, unfolded protein response and MYC target gene sets (Figure).


https://journals.lww.com/hemasphere/Pages/articleviewer.aspx?year=2019&issue=06001&article=01570&type=Fulltext

Message in reply to:
Found Transcriptional used in this wikipedia link discussing cell regulation. Hope we hear more on this.

https://en.wikipedia.org/wiki/Transcriptional_regulation



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist